Sphingolipids and Metabolic Disease

Volume 721 of the series Advances in Experimental Medicine and Biology pp 19-39

Sphingolipids and Cardiovascular Diseases: Lipoprotein Metabolism, Atherosclerosis and Cardiomyopathy

  • Xian-Cheng JiangAffiliated withDepartment of Cell Biology, Downstate Medical Center, State University of New York
  • , Ira J. GoldbergAffiliated withDepartment of Medicine, Division of Preventive Medicine and Nutrition, Columbia University
  • , Tae-Sik ParkAffiliated withLee Gil Ya Cancer and Diabetes Institute, Gachon University of Medicine and Science

* Final gross prices may vary according to local VAT.

Get Access


Heart disease is widely believed to develop from two pathological processes. Circulating lipoproteins containing the nondegradable lipid, cholesterol, accumulate within the arterial wall and perhaps are oxidized to more toxic lipids. Both lipid accumulation and vascular reaction to the lipids lead to the gradual thickening of the vascular wall. A second major process that in some circumstances is a primary event is the development of a local inflammatory reaction. This might be a reaction to vessel wall injury that accompanies infections, immune disease, and perhaps diabetes and renal failure. In this chapter, we will focus on the relationship between de novo synthesis of sphingolipids and lipid metabolism, atherosclerosis, and cardiomyopathy.